Key result
SGLT2 inhibitors demonstrate a beneficial effect on lowering office, home, ambulatory, and nocturnal blood pressure, offering potential implications for hypertension management and cardiorenal outcomes.
Why the study?
The pathophysiological extraglycemic mechanisms of SGLT2 inhibitors and their blood pressure-lowering effects, particularly on nocturnal blood pressure and cardiorenal outcomes in diabetic and non-diabetic individuals, warranted a summary of current knowledge.
Do SGLT2 inhibitors reduce blood pressure in diabetic and non-diabetic individuals?
Do SGLT2 inhibitors reduce blood pressure in diabetic and non-diabetic individuals?
SGLT2 inhibitors provide beneficial blood pressure-lowering effects, including nocturnal BP reduction, which may contribute to their positive cardiorenal outcomes in both diabetic and non-diabetic patients.
SGLT2 inhibitors may aid BP management; leaves open dedicated trials confirming cardiorenal benefits in nondiabetics.
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a newer class of drugs that have primarily been used in the treatment of type 2 diabetes. However, as new findings from clinical trials have become available, their indication has been expanded to include treatment of heart failure and chronic kidney disease without the presence of diabetes. The pathophysiological mechanisms of extraglycemic effects of SGLT2i are still being unraveled, but one of the most prominent consequences is a decrease in blood pressure, which has implications for hemodynamics and arterial stiffness. Recent findings indicate that this class of drugs has a beneficial effect on lowering nocturnal blood pressure (BP), with special importance in type 2 diabetes (DMT2), since unregulated nocturnal hypertension is associated with an increased incidence of cardiovascular (CV) events. In this mini-review, we have summarized current knowledge about the effects of SGLT2i on blood pressure, including office, home, and ambulatory BP, and potential implications for treatment of hypertension in diabetic and non-diabetic individuals, with positive effects on cardiorenal outcomes.
No takes yet. Share an insight, caveat, or question.
Bilić-Čurčić et al. (2022) conducted a review in Hypertension. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) was evaluated. SGLT2 inhibitors demonstrate a beneficial effect on lowering office, home, ambulatory, and nocturnal blood pressure, offering potential implications for hypertension management and cardiorenal outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: